<DOC>
	<DOCNO>NCT02696967</DOCNO>
	<brief_summary>The purpose study determine safety tolerability CLR325 heart failure patient determine clinical development drug indication warrant .</brief_summary>
	<brief_title>A Study CLR325 Chronic Stable Heart Failure Patients .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion : Written inform consent must obtain assessment perform . Able communicate well investigator , understand comply requirement study . Male female patient &gt; 18 year age . Patients must weigh 50kg 140 kg participate study . Patients cardiac ejection fraction ≤ 45 % assess within last 6 month . For PA catheter cohort , patient plan clinically indicate pulmonary artery catheter place prior randomization . At baseline , vital sign ( systolic diastolic blood pressure pulse rate ) assess sit position subject rest least five minute . Key Exclusion : Presence impair renal function indicate clinically significant abnormal creatinine value ( eGFR &lt; 30 ml/min/1.73m^2 calculate use MDRD equation ) . Patients value AST ALT &gt; 100 U/L measure within last 3 month randomization . Chronic infection Hepatitis B ( HBV ) Hepatitis C ( HCV ) . A positive Hepatitis B surface antigen ( HBsAg ) test exclude patient . Patients positive Hepatitis C antibody test HCV RNA level measure . Patients positive ( detectable ) HCV RNA exclude . Patients history chronic hepatitis noncardiac etiology . History active , clinically significant cardiac tachyarrhythmia , recurrent atrial fibrillation rapid ventricular response within last year . Anticoagulation patient atrial fibrillation manage per usual clinical practice patient undergo right heart catheterization . Patients admit inpatient set acute decompensated heart failure within last 30 day . Patients receive intravenous infusion cardiac inotrope ( e.g. , dobutamine milrinone ) last 24 hour prior randomization . Patients pulmonary capillary wedge pressure &lt; 10 mm Hg baseline . Patients change dose ACE , ARB , mineralocorticoid receptor antagonist , βblocker within last 2 week . The total weekly dose diuretic change 20 % within last week . Patients know significant valvular heart disease , include follow : Severe aortic stenosis ( Aortic Valve Area &lt; 1.0 cm^2 peak gradient &gt; 50 mmHg determine echocardiography ) Severe mitral stenosis Patients history acute coronary syndrome within last 60 day determine clinical enzymatic criterion . For PA catheter cohort , patient pulmonary capillary wedge pressure &lt; 10 mm Hg baseline . For echocardiographic cohort , patient estimate central venous pressure &lt; 5mm Hg baseline echocardiogram determine inferior vena cava criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>